HCA Healthcare, Inc. provided earnings guidance for the year 2023. For the year, the company expects revenues to be in the range of $61.5 billion to $63.5 billion, net income attributable to the company to be in the range of $4.525 billion to $4.895 billion, EPS (diluted) to be in the range of $16.40 to $17.60 per diluted share. The Company's 2023 guidance contains a number of assumptions, including, among others, the Company's current expectations regarding the impact of the COVID-19 pandemic as well as general economic conditions, including inflation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
324.4 USD | +2.17% |
|
+1.28% | +19.84% |
Jul. 12 | Bernstein Adjusts Price Target on HCA Healthcare to $362 From $317 | MT |
Jul. 09 | Barclays Adjusts HCA Healthcare's Price Target to $376 From $367, Keeps Overweight Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.84% | 84.94B | |
-25.24% | 74.07B | |
-1.20% | 26.15B | |
+4.56% | 18.03B | |
-9.29% | 17.38B | |
+4.52% | 16.01B | |
+78.16% | 13.7B | |
+77.84% | 13.13B | |
-26.14% | 12.74B | |
+35.12% | 12.41B |
- Stock Market
- Equities
- HCA Stock
- News HCA Healthcare, Inc.
- HCA Healthcare, Inc. Provides Earnings Guidance for the Year 2023